FDA gives orphan drug status to ProQR Therapeutics' QR-313 for dystrophic epidermolysis bullosa Sep. 21, 2017
EMA committee recommends approval of guselkumab for moderate to severe plaque psoriasis Sep. 18, 2017
Phase III ESSENCE study of SD-101 in epidermolysis bullosa does not meet primary endpoint Sep. 14, 2017
FDA grants breakthrough therapy designation to EB-101 for recessive dystrophic epidermolysis bullosa Aug. 30, 2017
RSS